Search
Search
About
Log in
Join
Experiences with
Sovaldi
Posts
Communities
77 public posts
Filter results
Are new hepatitis C drugs worth the money? A Boston doctor says yes
Since it was approved in December 2013,
Sovaldi
has been blamed dozens of times by health care insurers as a prime reason for operating losses.
Since it was approved in December 2013,
Sovaldi
has been blamed dozens of times by health care insurers as a prime reason for operating losses.
kcohen
in
HFI Connect - Hepatitis
9 years ago
Concerns Over State Restrictions on New Hepatitis C Drugs
They found that 42 states have put some sort of restriction on
Sovaldi
(sofosbuvir) since it came out in 2013, which costs nearly $84,000 for a standard 12-week course of treatment.
They found that 42 states have put some sort of restriction on
Sovaldi
(sofosbuvir) since it came out in 2013, which costs nearly $84,000 for a standard 12-week course of treatment.
kcohen
in
HFI Connect - Hepatitis
9 years ago
State Moves To Make Costly Hepatitis C Drugs More Accessible To Medicaid Patients
Article: http://www.courant.com/politics/hc-
sovaldi
-more-accessible-0516-20150515-story.html
Article: http://www.courant.com/politics/hc-
sovaldi
-more-accessible-0516-20150515-story.html
kcohen
in
HFI Connect - Hepatitis
9 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
California could spend nearly $5 billion on HCV drugs over next year
The wholesale acquisition cost price of $117,000 is based on the following regimens: 8, 12 and 24 weeks of Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) and 12 and 24 weeks of
Sovaldi
(sofosbuvir, Gilead Sciences) plus ribavirin.
The wholesale acquisition cost price of $117,000 is based on the following regimens: 8, 12 and 24 weeks of Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) and 12 and 24 weeks of
Sovaldi
(sofosbuvir, Gilead Sciences) plus ribavirin.
kcohen
in
HFI Connect - Hepatitis
9 years ago
State restrictions for hepatitis C drug may go too far
In 2013, the U.S. approved a new drug known as sofosbuvir, which is marketed here as
Sovaldi
by Gilead. Given in combination with other drugs, sofosbuvir achieves very high cure rates in patients with the difficult to treat infection.
In 2013, the U.S. approved a new drug known as sofosbuvir, which is marketed here as
Sovaldi
by Gilead. Given in combination with other drugs, sofosbuvir achieves very high cure rates in patients with the difficult to treat infection.
kcohen
in
HFI Connect - Hepatitis
9 years ago
State restrictions for hepatitis C drug may go too far
In 2013, the U.S. approved a new drug known as sofosbuvir, which is marketed here as
Sovaldi
by Gilead. Given in combination with other drugs, sofosbuvir achieves very high cure rates in patients with the difficult to treat infection.
In 2013, the U.S. approved a new drug known as sofosbuvir, which is marketed here as
Sovaldi
by Gilead. Given in combination with other drugs, sofosbuvir achieves very high cure rates in patients with the difficult to treat infection.
kcohen
in
HFI Connect - Hepatitis
9 years ago
Harvoni and Sovaldi/Daclatasvir Safer to Mix With HIV Meds
Such DDIs would be expected with 70 percent of the HIV regimens if combined with Olysio/
Sovaldi
, 61 percent with Viekira Pak, 64 percent with Harvoni, and 47 percent with
Sovaldi
/daclatasvir.
Such DDIs would be expected with 70 percent of the HIV regimens if combined with Olysio/
Sovaldi
, 61 percent with Viekira Pak, 64 percent with Harvoni, and 47 percent with
Sovaldi
/daclatasvir.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Hepatitis C Patients Take Extreme Measures for Cheaper Cures
Some people living with the hepatitis C virus (HCV) are going to extreme lengths to obtain cheaper versions of Gilead Science’s HCV drug
Sovaldi
(sofosbuvir).
Some people living with the hepatitis C virus (HCV) are going to extreme lengths to obtain cheaper versions of Gilead Science’s HCV drug
Sovaldi
(sofosbuvir).
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Hepatitis C Patients Take Extreme Measures for Cheaper Cures
Some people living with the hepatitis C virus (HCV) are going to extreme lengths to obtain cheaper versions of Gilead Science’s HCV drug
Sovaldi
(sofosbuvir).
Some people living with the hepatitis C virus (HCV) are going to extreme lengths to obtain cheaper versions of Gilead Science’s HCV drug
Sovaldi
(sofosbuvir).
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
8 Weeks of Daclatasvir/Sovaldi Cures Some With HCV/HIV
All the participants who took eight weeks of daclatasvir and
Sovaldi
were treatment naive.. Of those treated for 12 weeks, 101 were treatment naive and 52 were treatment experienced.
All the participants who took eight weeks of daclatasvir and
Sovaldi
were treatment naive.. Of those treated for 12 weeks, 101 were treatment naive and 52 were treatment experienced.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
8 Weeks of Daclatasvir/Sovaldi Cures Some With HCV/HIV
All the participants who took eight weeks of daclatasvir and
Sovaldi
were treatment naive.. Of those treated for 12 weeks, 101 were treatment naive and 52 were treatment experienced.
All the participants who took eight weeks of daclatasvir and
Sovaldi
were treatment naive.. Of those treated for 12 weeks, 101 were treatment naive and 52 were treatment experienced.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
World Health Organization Throws Weight Behind Hep C Treatments
Included in the list are Gilead Sciences’
Sovaldi
(sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.
Included in the list are Gilead Sciences’
Sovaldi
(sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
World Health Organization Throws Weight Behind Hep C Treatments
Included in the list are Gilead Sciences’
Sovaldi
(sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.
Included in the list are Gilead Sciences’
Sovaldi
(sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Sanders Urges Veterans Affairs to Break Hepatitis C Patents
The politician wrote an open letter to the VA asking the agency to override patent protections held by Gilead Sciences for
Sovaldi
(sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) treatments, as well as patents held by AbbVie for its Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) combo regimen
The politician wrote an open letter to the VA asking the agency to override patent protections held by Gilead Sciences for
Sovaldi
(sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) treatments, as well as patents held by AbbVie for its Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) combo regimen
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Cure for Almost All Hep C-Positive Liver Transplantees
Bristol-Myers Squibb’s daclatasvir and Gilead Sciences’
Sovaldi
(sofosbuvir), with or without ribavirin, offer near-perfect hepatitis C virus (HCV) cure rates among those who have received a liver transplant.
Bristol-Myers Squibb’s daclatasvir and Gilead Sciences’
Sovaldi
(sofosbuvir), with or without ribavirin, offer near-perfect hepatitis C virus (HCV) cure rates among those who have received a liver transplant.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Daclatasvir Plus Sovaldi Shows Promise Curing Hard-to-Treat Hep C
Bristol-Myers Squibb’s daclatasvir and Gilead Sciences’
Sovaldi
(sofosbuvir), with or without ribavirin, seem likely to lead to relatively good cure rates among people with genotype 3 of hepatitis C virus.
Bristol-Myers Squibb’s daclatasvir and Gilead Sciences’
Sovaldi
(sofosbuvir), with or without ribavirin, seem likely to lead to relatively good cure rates among people with genotype 3 of hepatitis C virus.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Patent for hepatitis C treatment would cut access for millions, groups say:
Similar filings against the company have already been made in India, Egypt and the European Union.With its attempts to hold exclusive rights to sofosbuvir, which the company has branded
Sovaldi
, Gilead was “abusing patent laws by claiming existing public knowledge as its own,” Priti Radhakrishnan, a
Similar filings against the company have already been made in India, Egypt and the European Union.With its attempts to hold exclusive rights to sofosbuvir, which the company has branded
Sovaldi
, Gilead was “abusing patent laws by claiming existing public knowledge as its own,” Priti Radhakrishnan, a
mwright
in
HFI Connect - Hepatitis
9 years ago
Daclatasvir and Sovaldi Cure High Rates of Genotype 1 of Hep C
A recent trial suggests that Bristol-Myers Squibb’s daclatasvir plus Gilead Sciences’
Sovaldi
(sofosbuvir), with or without ribavirin, cures high rates of people with genotype 1 of hepatitis C virus (HCV), including those with cirrhosis.
A recent trial suggests that Bristol-Myers Squibb’s daclatasvir plus Gilead Sciences’
Sovaldi
(sofosbuvir), with or without ribavirin, cures high rates of people with genotype 1 of hepatitis C virus (HCV), including those with cirrhosis.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Olysio-Sovaldi Combo Cures High Rates of Hep C Genotype 1
Twelve weeks of Janssen’s Olysio (simeprevir) and Gilead Sciences’
Sovaldi
(sofosbuvir) boasted near-perfect cure results in a recent trial treating people with genotype 1 of hepatitis C virus (HCV) who did not have cirrhosis.
Twelve weeks of Janssen’s Olysio (simeprevir) and Gilead Sciences’
Sovaldi
(sofosbuvir) boasted near-perfect cure results in a recent trial treating people with genotype 1 of hepatitis C virus (HCV) who did not have cirrhosis.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Options for Treating Hepatitis C in Those With Advanced Cirrhosis
Seventy-seven percent (55 of 71) of those with genotype 1 who took
Sovaldi
and Olysio, most of them for 12 weeks, achieved an SVR4, as did 81 percent (13 of 16) of those with genotype 1 who took
Sovaldi
, Olysio and ribavirin for 12 weeks.
Seventy-seven percent (55 of 71) of those with genotype 1 who took
Sovaldi
and Olysio, most of them for 12 weeks, achieved an SVR4, as did 81 percent (13 of 16) of those with genotype 1 who took
Sovaldi
, Olysio and ribavirin for 12 weeks.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
1
2
3
4
Next page
Filter results
Clear filters
Posted in
All communities
HFI Connect - Hepatitis
57 results
British Liver Trust
9 results
Hepatitis C Support
4 results
View top 10 communities
Sort by
Most Relevant
Newest